Reduces the rate of cardiovascular death; myocardial infarction (MI); stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction; reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
In the management of ACS: loading dose - 180mg then 90mg BD for a year followed by 60mg BD (used with a daily maintenance dose of aspirin of 75-100mg).
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
The drug and its major metabo- lite are platelet aggregation inhibitors that revers- ibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activa- tion.
Do not use in case of active patho- logical bleeding, history of intracranial hemor- rhage and in patient undergoing urgent coronary artery bypass graft surgery; stopping of the treat- ment suddenly will increase the risk of MI, stroke, and death.
Allergy to the drug or excipi- ents; active or history of pathological bleeding e.g. peptic ulcer and intracranial hemorrhage.
It is known to be superior to clopidogrel; avoid use in case of severe hepatic impairment.